KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Stereotaxis (STXS) Research & Development (2016 - 2025)

Stereotaxis (STXS) has disclosed Research & Development for 16 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 2.87% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.4 million through Dec 2025, down 3.86% year-over-year, with the annual reading at $9.4 million for FY2025, 3.86% down from the prior year.
  • Research & Development for Q4 2025 was $2.7 million at Stereotaxis, up from $2.5 million in the prior quarter.
  • The five-year high for Research & Development was $2.9 million in Q2 2022, with the low at $1.8 million in Q2 2025.
  • Average Research & Development over 5 years is $2.5 million, with a median of $2.5 million recorded in 2021.
  • The sharpest move saw Research & Development soared 37.43% in 2021, then dropped 21.82% in 2025.
  • Over 5 years, Research & Development stood at $2.6 million in 2021, then dropped by 8.22% to $2.4 million in 2022, then dropped by 7.83% to $2.2 million in 2023, then grew by 26.13% to $2.8 million in 2024, then decreased by 2.87% to $2.7 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $2.7 million, $2.5 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.